Artiva Biotherapeutics, Inc. ARTV Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $21.42M-30.6% | $27.16M-32.9% | $25.97M-53.7% | $28.93M-16.2% | $30.86M-36.3% | ||
| $65.83M-51.4% | $81.31M-44.0% | $97.46M+7.4% | $113.9M+825% | $135.56M— | ||
| $88.74M-47.8% | $112.67M-40.3% | $129.52M-14.0% | $149.07M+200% | $170M— | ||
| $6.22M-11.9% | $6.62M+3.9% | $6.98M+1.8% | $6.89M-5.9% | $7.06M— | ||
| $105.96M-44.6% | $130.94M-37.5% | $148.86M-34.0% | $169.39M+123% | $191.26M— | ||
| $2.29M+12.3% | $355K-68.3% | $848K-30.2% | $1.22M+47.6% | $2.04M+139% | ||
| $11K-91.3% | $44K-63.9% | $75K-37.0% | $106K-8.6% | $126K— | ||
| $10.88M-10.8% | $13.09M+6.8% | $11.12M-16.3% | $10.77M-0.5% | $12.2M— | ||
| $18.11M-19.4% | $20.97M-8.6% | $19.64M-20.2% | $20.35M-59.8% | $22.48M— | ||
| —— | 3K0.0% | —— | —— | —— | ||
| -$354.07M-32.6% | -$330.55M-34.0% | -$309.78M-34.3% | -$288.25M-35.3% | -$267M— | ||
| $87.85M-48.0% | $109.97M-41.1% | $129.22M-35.7% | $149.04M+178% | $168.78M+197% | ||
| $105.96M-44.6% | $130.94M-37.5% | $148.86M-34.0% | $169.39M+123% | $191.26M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Artiva Biotherapeutics, Inc.'s total assets?
- Artiva Biotherapeutics, Inc. (ARTV) holds $106.0M in total assets, down 44.6% year over year.
- How much debt does Artiva Biotherapeutics, Inc. have?
- Artiva Biotherapeutics, Inc. carries $10.3M in total debt against $87.8M of shareholders' equity, a debt-to-equity ratio of 0.12.
- How much cash does Artiva Biotherapeutics, Inc. have?
- Artiva Biotherapeutics, Inc. holds $21.4M in cash and equivalents.
- Can Artiva Biotherapeutics, Inc. cover its short-term obligations?
- Its current ratio is 8.16 — current assets exceed current liabilities.
- Where does Artiva Biotherapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.